TABLE 1.
Baseline Characteristics of Patients
| Patient Characteristic | Completed 2 y of ICIs (n = 96) | Discontinued ICIs Early (n = 43) |
|---|---|---|
| Age, median (range), y | 65 (38‐87) | 69.5 (43‐86) |
| Age ≥ 65 y, No. (%) | 49 (51.0) | 30 (69.8) |
| Sex, No. (%) | ||
| Male | 82 (85.4) | 40 (93.0) |
| Female | 14 (14.6) | 3 (7.0) |
| ECOG PS, No. (%) | ||
| 0 | 19 (19.8) | 12 (27.9) |
| 1 | 71 (74.0) | 28 (65.1) |
| ≥2 | 6 (6.2) | 3 (7.0) |
| Smoking history, No. (%) | ||
| Current or former | 69 (71.9) | 37 (86.0) |
| Never | 27 (28.1) | 5 (11.6) |
| Unknown | 0 (0.0) | 1 (2.3) |
| Histology, No. (%) | ||
| Squamous | 20 (20.8) | 12 (27.9) |
| Nonsquamous | 65 (67.7) | 24 (55.8) |
| Other | 9 (9.4) | 7 (16.3) |
| Unknown | 2 (2.1) | 0 (0.0) |
| Brain metastasis, No. (%) | 27 (28.1) | 8 (18.6) |
| EGFR mutation status, No. (%) | ||
| Mutant | 4 (4.2) | 2 (4.7) |
| Wild type | 92 (95.8) | 40 (93.0) |
| Unknown | 0 (0.0) | 1 (2.3) |
| ALK translocation present, No. (%) | ||
| Yes | 2 (2.1) | 0 (0.0) |
| No | 94 (97.9) | 41 (95.3) |
| Unknown | 0 (0.0) | 2 (4.3) |
| PD‐L1 status, No. (%) | ||
| ≥50% | 94 (97.9) | 38 (88.4) |
| 1%‐49% | 2 (2.1) | 3 (7.0) |
| <1% | 0 (0.0) | 2 (4.7) |
| Type of immune checkpoint inhibitor, No. (%) | ||
| Pembrolizumab | 61 (63.5) | 24 (55.8) |
| Nivolumab | 29 (30.2) | 14 (32.6) |
| Atezolizumab | 4 (4.2) | 3 (7.0) |
| Pembrolizumab + chemotherapy | 0 (0.0) | 2 (4.7) |
| Other | 2 (2.1) | 0 (0.0) |
| Lines of therapy for ICIs, No. (%) | ||
| 1 | 10 (10.4) | 6 (14.0) |
| 2 | 61 (63.5) | 30 (69.8) |
| ≥3 | 25 (26.1) | 7 (16.2) |
Abbreviations: ALK, anaplastic lymphoma kinase; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; ICI, immune checkpoint inhibitor; PD‐L1, programmed cell death ligand 1; PS, performance status.